Stay updated with breaking news from Biocon Sdn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Insight Partners published latest research study on "Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [Long...
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins.
MBR has recognised the company’s 562,000 sq. ft. facility as the first and largest integrated insulin manufacturer in Malaysia.
This is Mylan's third voluntary recall of insulin glargine this year, caused by the potential for the labels to be missing on some prefilled pens.
On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for...